SCHEMBL7148417

SCHEMBL7148417

O=C(O)C(Cc1ccccc1)CS(=O)(=O)N1CCN(c2ccc(F)cc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.55
TP53 P04637 2/20 0.53
CYP3A4 P08684 1/20 0.52
MMP13 P45452 1/20 0.52
MMP14 P50281 1/20 0.52
LMNA P02545 3/20 0.51
GFER P55789 1/20 0.49
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
HPGD P15428 1/20 0.48
GRM5 P41594 1/20 0.46
MAPT P10636 1/20 0.46
TSHR P16473 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7151093 0.87 KDM4E (0.51) POLBTP53CYP3A4MMP13MMP14
SCHEMBL7145234 0.84 MMP13 (0.52) POLBTP53CYP3A4MMP13MMP14
SCHEMBL7139295 0.82 MMP13 (0.50) POLBTP53CYP3A4MMP13MMP14
SCHEMBL4812127 0.82 MMP13 (0.58) POLBTP53CYP3A4MMP13MMP14
SCHEMBL7333389 0.81 CYP1A2 (0.54) ALDH1A1HPGDTSHRMEN1KMT2A
SCHEMBL7330813 0.80 HSD17B10 (0.50) POLBALDH1A1TSHRKMT2A
SCHEMBL7301756 0.80 LMNA (0.56) POLBLMNAALDH1A1MAPTTSHR
SCHEMBL7338169 0.80 HSD17B10 (0.50) POLBALDH1A1TSHRKMT2A
SCHEMBL8909332 0.80 LMNA (0.56) POLBLMNAALDH1A1MAPTTSHR
SCHEMBL7146296 0.80 MMP13 (0.48) POLBTP53CYP3A4MMP13MMP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030139419-A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents ASTRAZENECA AB (SE) 2003-07-24 US disclosed
EP-1261595-A1 ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS AstraZeneca AB (SE) 2002-12-04 EP disclosed
WO-2001062751-A1 ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS ASTRAZENECA AB (SE) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139419-A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents MMP13, MMP3, MMP2 POLB 2666/4885TP53 3824/4885CYP3A4 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.